Perspective Therapeutics, a clinical-stage outfit developing targeted radiopharmaceutical cancer therapies, just dropped their Q2 2025 numbers. Revenue hit $0.3 million, beating expectations. Mostly NIH grant money. But hey, the net loss ballooned to $21.5 million. R&D costs went through the roof.

Cash position? Still solid. $192 million in the bank as of June 30, 2025. Should keep the lights on till late 2026.

They're pushing forward with their clinical stuff. VMT-α-NET for neuroendocrine tumors. VMT01 for melanoma. And PSV359, targeting FAP-α tumors. That last one? Two patients dosed by July 31. More trial sites coming online.

Their secret sauce? Lead-212, an alpha-emitting isotope. It's kind of a two-for-one deal - diagnose and zap cancer cells. They call it "theranostics". Sounds fancy. Supposed to be precise with less toxicity. We'll see.

R&D spending shot up 79% from last year. Hit $16.6 million in Q2. More trials, more staff, more drug production. It adds up.

What's next? They're promising updates on clinical data and dose exploration for their main programs. Timeline's a bit fuzzy - somewhere in the next 12 to 18 months. Seems like they're all in on pushing their pipeline forward.